In a 52-year-old man with hypertension, an α1-adrenergic antagonist is prescribed. Which of the following is the most common second messenger system activated by the α1-adrenergic receptor that the drug is blocking?

Explanation

## α1-Adrenergic Receptor Signaling and Second Messengers ### Clinical Context: α1-Adrenergic Antagonists in Hypertension α1-Adrenergic antagonists (doxazosin, terazosin, prazosin) are used to treat hypertension by blocking α1-adrenergic receptors on vascular smooth muscle. Understanding the second messenger system they block is essential for comprehending their mechanism of action. ### α1-Adrenergic Receptor Coupling **Key Point:** α1-Adrenergic receptors are coupled to **Gq/11 proteins**, which activate **phospholipase C (PLC)**, leading to the generation of **IP3 and DAG** as second messengers. This is the most common signaling pathway for α1-adrenergic receptors. ### Mechanism of IP3/DAG Pathway in Vascular Smooth Muscle 1. **Agonist binding:** Norepinephrine/epinephrine binds α1-adrenergic receptor 2. **G-protein activation:** Gq/11 protein dissociates and activates PLC 3. **PIP2 hydrolysis:** PLC cleaves PIP2 → **IP3** + **DAG** 4. **IP3 signaling:** IP3 diffuses to sarcoplasmic reticulum → opens IP3 receptor (calcium channel) → **Ca²⁺ release** 5. **DAG signaling:** DAG activates protein kinase C (PKC) → phosphorylates MLCK (myosin light chain kinase) 6. **Contraction:** Increased intracellular Ca²⁺ + PKC activation → smooth muscle contraction → vasoconstriction ### Comparison of Adrenergic Receptor Signaling Pathways | Receptor | G-Protein | Effector | Second Messenger | Tissue Effect | Vascular Effect | | --- | --- | --- | --- | --- | --- | | **α1-Adrenergic** | **Gq/11** | **PLC** | **IP3/DAG** | Contraction | **Vasoconstriction** | | α2-Adrenergic | Gi/o | ↓ AC | ↓ cAMP | Inhibition | Vasoconstriction (presynaptic) | | β1-Adrenergic | Gs | ↑ AC | ↑ cAMP | Increased contractility | Vasodilation (indirect) | | β2-Adrenergic | Gs | ↑ AC | ↑ cAMP | Relaxation | Vasodilation | ### Why IP3/DAG Is the Correct Answer **High-Yield:** α1-adrenergic receptors are **exclusively coupled to Gq proteins** and activate the IP3/DAG pathway. This is the physiological mechanism by which norepinephrine causes vascular smooth muscle contraction and blood pressure elevation. α1-antagonists block this pathway, preventing IP3-mediated calcium release and PKC activation, thereby causing vasodilation and blood pressure reduction. ### Clinical Pearl: Selectivity of α1-Antagonists α1-Antagonists are selective for α1-adrenergic receptors and do NOT block β-adrenergic receptors (which use cAMP). This selectivity is why they cause vasodilation without the reflex tachycardia that would occur if β-adrenergic signaling were also blocked. However, some patients experience mild reflex tachycardia due to baroreceptor-mediated sympathetic activation. ### Diagram: IP3/DAG Pathway in Vascular Smooth Muscle ```mermaid flowchart TD A["α1-Adrenergic Agonist<br/>(Norepinephrine)"]:::outcome --> B["α1-Adrenergic Receptor"]:::outcome B --> C["Gq/11 Protein Activation"]:::action C --> D["Phospholipase C Activation"]:::action D --> E["PIP2 Hydrolysis"]:::action E --> F["IP3 Generation"]:::outcome E --> G["DAG Generation"]:::outcome F --> H["IP3 Receptor Activation<br/>on Sarcoplasmic Reticulum"]:::action H --> I["Intracellular Ca²⁺ Release"]:::action G --> J["Protein Kinase C Activation"]:::action I --> K["Smooth Muscle Contraction"]:::outcome J --> K K --> L["Vasoconstriction<br/>↑ Blood Pressure"]:::urgent L --> M["α1-Antagonist Blocks<br/>This Pathway"]:::action ``` **Mnemonic:** **Gq = IP3/DAG pathway** (remember: "Gq" sounds like "queue" → think of a line of calcium ions waiting to be released via IP3). **Gs = cAMP pathway** ("Gs" = stimulatory, activates adenylyl cyclase).